Recruiting
Phase 2

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT05721248

Conditions

Breast Cancer

Metastatic Breast Cancer

HER2-positive Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cessation of anti-HER2 treatment

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information